SK Bioscience302440
SK Bioscience (302440) Preliminary Earnings, Nov 5, 2026
Filing date ·
SK Bioscience reported preliminary Q3 2026 results (consolidated): Revenue of KRW 182.4 billion (+21.0% year over year), operating profit of -KRW 11.2 billion,…
Sign in to read this filing in detail
Continue to the filing details and any available analysis after signing in.
Filing lists and official source links are available without signing in.